PCI Approves Two MPharm Courses with 15 Seats Each at Gorakhpur University from 2026-27

According to university officials, approval has been granted for MPharm courses in Pharmaceutical Chemistry and Pharmaceutics, with 15 seats each. The university had applied to PCI for permission to start these postgraduate programmes, which has now been formally granted.

The move is expected to boost opportunities in areas such as drug research, manufacturing, quality control, and the broader pharmaceutical industry. PCI has also directed the university to ensure compliance with norms, including appointment of teaching and technical staff and updating required details on the AEBAS portal.

University Vice-Chancellor Prof. Poonam Tandon stated that the approval will help establish a complete academic ecosystem for pharmacy education on campus, ranging from teaching to advanced research. She highlighted that the development reflects improved infrastructure, modern laboratories, qualified faculty, and a research-oriented environment at the institution.

The approval is particularly significant as the university had already received permission in previous years to run DPharm and BPharm courses, with 60 seats each, and later expansion of BPharm seats to 100. Additionally, PhD programmes in pharmacy were introduced from the 2025–26 session. With the inclusion of MPharm, the university will now offer the full spectrum of pharmacy education.

According to a recent Amar Ujala report, students from eastern Uttar Pradesh often had to move to other states to pursue postgraduate or doctoral studies in pharmacy. The introduction of MPharm courses locally is expected to reduce this migration and strengthen regional access to higher education in the pharmaceutical field.

The university expressed confidence that this step will position it as a leading centre for pharmacy education and innovation in the state.